Next Article in Journal
Sulfonate-Functionalized Mesoporous Silica Nanoparticles as Carriers for Controlled Herbicide Diquat Dibromide Release through Electrostatic Interaction
Next Article in Special Issue
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70
Previous Article in Journal
Arctigenin Reduces Myofibroblast Activities in Oral Submucous Fibrosis by LINC00974 Inhibition
Previous Article in Special Issue
Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases
Open AccessReview

HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases

1
Department of Pharmacology, Chonnam National University Medical School, Hwasun 58128, Korea
2
Division of Clinical Pharmacology, Chonnam National University Hospital, Gwangju 61469, Korea
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(6), 1329; https://doi.org/10.3390/ijms20061329
Received: 25 January 2019 / Revised: 5 March 2019 / Accepted: 12 March 2019 / Published: 16 March 2019
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease)
Fibrosis is characterized by excessive deposition of the extracellular matrix and develops because of fibroblast differentiation during the process of inflammation. Various cytokines stimulate resident fibroblasts, which differentiate into myofibroblasts. Myofibroblasts actively synthesize an excessive amount of extracellular matrix, which indicates pathologic fibrosis. Although initial fibrosis is a physiologic response, the accumulated fibrous material causes failure of normal organ function. Cardiac fibrosis interferes with proper diastole, whereas pulmonary fibrosis results in chronic hypoxia; liver cirrhosis induces portal hypertension, and overgrowth of fibroblasts in the conjunctiva is a major cause of glaucoma surgical failure. Recently, several reports have clearly demonstrated the functional relevance of certain types of histone deacetylases (HDACs) in various kinds of fibrosis and the successful alleviation of the condition in animal models using HDAC inhibitors. In this review, we discuss the therapeutic potential of HDAC inhibitors in fibrosis-associated human diseases using results obtained from animal models. View Full-Text
Keywords: fibrosis; HDAC; HDAC inhibitor; therapeutics fibrosis; HDAC; HDAC inhibitor; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Yoon, S.; Kang, G.; Eom, G.H. HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases. Int. J. Mol. Sci. 2019, 20, 1329. https://doi.org/10.3390/ijms20061329

AMA Style

Yoon S, Kang G, Eom GH. HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases. International Journal of Molecular Sciences. 2019; 20(6):1329. https://doi.org/10.3390/ijms20061329

Chicago/Turabian Style

Yoon, Somy; Kang, Gaeun; Eom, Gwang H. 2019. "HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases" Int. J. Mol. Sci. 20, no. 6: 1329. https://doi.org/10.3390/ijms20061329

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop